These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 561124)

  • 1. Serum lipoproteins and C567-INH activity.
    Lint TF; Behrends CL; Gewurz H
    J Immunol; 1977 Sep; 119(3):883-8. PubMed ID: 561124
    [No Abstract]   [Full Text] [Related]  

  • 2. Activation of the complement attack mechanism in the fluid phase and its control by C567-INH: lysis of normal erythrocytes initiated by zymosan, endotoxin, and immune complexes.
    Lint TF; Behrends CL; Baker PJ; Gewurz H
    J Immunol; 1976 Nov; 117(5 Pt 1):1440-6. PubMed ID: 1002985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of the inhibition of C56-initiated lysis (reactive lysis). IV. Antagonism of the inhibitory activity c567-INH by poly-L-lysine.
    McLeod B; Baker P; Behrends C; Gewurz H
    Immunology; 1975 Feb; 28(2):379-90. PubMed ID: 47309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyanate as an inactivator of complement proteins.
    Schultz DR; Arnold PI
    J Immunol; 1975 Dec; 115(6):1558-65. PubMed ID: 1184967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restriction of complement-mediated membrane damage by the eighth component of complement: a dual role for C8 in the complement attack sequence.
    Nemerow GR; Yamamoto KI; Lint TF
    J Immunol; 1979 Sep; 123(3):1245-52. PubMed ID: 469249
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies on the inhibition of C56-initiated lysis (reactive lysis). V. The roleof C567-INH in the regulation of complement-dependent haemolysis initiated by cobravenom factor.
    McLeod B; Lint TF; Baker P; Behrends C; Gewurz H
    Immunology; 1975 Apr; 28(4):741-54. PubMed ID: 1171082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C567-initiated cytolysis of lymphoid cells: description of the phenomenon and studies on its control by C567 inhibitors.
    Baker PJ; Lint TF; Mortensen RF; Gewurz H
    J Immunol; 1977 Jan; 118(1):198-202. PubMed ID: 830747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The C5b-6 complex: reaction with C7, C8, C9.
    Podack ER; Biesecker G; Kolb WP; Müller-Eberhard HJ
    J Immunol; 1978 Aug; 121(2):484-90. PubMed ID: 681745
    [No Abstract]   [Full Text] [Related]  

  • 9. Complement lysis of human erythrocytes. II. A unique interaction of human C8 and C9 with paroxysmal nocturnal hemoglobinuria erythrocytes.
    Packman CH; Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1980 Jun; 124(6):2818-23. PubMed ID: 7189536
    [No Abstract]   [Full Text] [Related]  

  • 10. The C5b-6 complex: formation, isolation, and inhibition of its activity by lipoprotein and the S-protein of human serum.
    Podack ER; Kolb WP; Müller-Eberhard HJ
    J Immunol; 1978 Jun; 120(6):1841-8. PubMed ID: 659879
    [No Abstract]   [Full Text] [Related]  

  • 11. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
    Hänsch GM; Hammer CH; Mayer MM; Shin ML
    J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of desoxycholate, phosphatidylcholine vesicles, lipoprotein and of the S-protein to complexes of terminal complement components.
    Podack ER; Müller-Eberhard HJ
    J Immunol; 1978 Sep; 121(3):1025-30. PubMed ID: 690431
    [No Abstract]   [Full Text] [Related]  

  • 13. Deviated lysis: Transfer of complement lytic activity to unsensitized cells II. Generation of the activity by inulin and by antigen antibody complexes.
    Rother U; Hänsch G; Rother K
    Z Immunitatsforsch Immunobiol; 1976 Aug; 151(1):442-54. PubMed ID: 785847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.
    Kitamura H; Tsuboi M
    Immunology; 1989 Feb; 66(2):264-9. PubMed ID: 2925225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemolytic assays in agarose plates for components of the classical complement pathway: interference by the alternative pathway.
    Martin A; Lachmann PJ
    Clin Exp Immunol; 1977 Jan; 27(1):13-22. PubMed ID: 321155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of the number of lytic sites in biconcave and spheroid erythrocyte ghosts after complement lysis.
    Bauer J; Podack ER; Valet G
    J Immunol; 1979 May; 122(5):2032-6. PubMed ID: 448115
    [No Abstract]   [Full Text] [Related]  

  • 17. Deviated lysis: transfer of complement lytic activity to unsensitized cells. I. Generation of the transferable activity on the surface of complement resistant bacteria.
    Rother U; Hänsch G; Menzel J; Rother K
    Z Immunitatsforsch Exp Klin Immunol; 1974 Nov; 148(2):172-86. PubMed ID: 4283273
    [No Abstract]   [Full Text] [Related]  

  • 18. The properdin pathway: mechanisms of complement activation and analogies to the classical pathway.
    Fearon DT; Austen KF; Ruddy S
    Rheumatology; 1975; 6():2-16. PubMed ID: 1105744
    [No Abstract]   [Full Text] [Related]  

  • 19. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
    Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
    Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deviated lysis: transfer of complement lytic activity to unsensitized cells. IV. Parital isolation of the activity.
    Hänsch G; Rother U; Rother K
    Z Immunitatsforsch Immunobiol; 1977 Apr; 153(1):48-59. PubMed ID: 868206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.